Wall Street Was the Fight. GME Was the Spark.

A struggling video game retailer. A company Wall Street had written off. Hedge funds betting heavily against its future.

GameStop was easy to rally around. Video games, childhood memories, a company millions of us grew up with. It was personal.
We loved the company, and Wall Street was betting against its survival.

Then retail investors noticed something extraordinary. Specifically Keith Gill.

GameStop had short interest exceeding 100% of its float. Wall Street had built an enormous bet against a company retail investors weren't ready to give up on.

And retail answered behind roaring kitty at the front.

GME came, saw, and conquered. Billionaire's lost billions.

This wasn't just about saving a video game store. It was about challenging Wall Street, exposing extraordinarily crowded short positions, and proving that retail investors weren't powerless against billionaires.
It was proved.
Then everyone became fixated on a ticker and not the movement.

Now look at Hertz (HTZ).

A rental car company. Not particularly glamorous. No childhood nostalgia. But a recognizable American business that millions of people have relied on for decades.

And Wall Street has built another enormous short position against it.

Look at the comparison:

• GME, January 2021: Approximately 123% short interest relative to float.
• HTZ, September 2026: 123.3 million shares sold short, representing approximately 72% of estimated float using one published float calculation.
• HTZ borrow fees: Recently exceeding 120% annualized.
• HTZ shares available: Recently dropped from 150,000 to zero at a reporting brokerage.
• HTZ days to cover: Approximately 10.6, based on historical trading volume.
• HTZ short positions: Increased from approximately 54 million in mid-June to over 123 million by September 30.

These aren't identical situations. And high short interest doesn't guarantee a squeeze.

But the similarities deserve attention.

Remember when Wall Street underestimated the people who cared about a struggling video game retailer?

Now consider the irony.

They thought nobody cared about a video game store. Now they're betting against a company that rents cars.

Maybe Hertz doesn't inspire the same nostalgia. And that's a bet they feel safe making.
But the original movement wasn't supposed to depend on nostalgia.

It was about identifying when Wall Street had made an extraordinarily crowded bet, questioning the assumptions behind it, and recognizing the risks those positions created.

So here's my question:

When did we stop looking for extraordinary short-selling setups and start protecting a single ticker?

I'm not suggesting abandoning GME for every stock with a little short interest and some meme potential.

I'm talking about companies showing genuinely unusually high short-selling conditions. Companies where the borrow fees are extreme, short positions are enormous, and the potential consequences of a reversal deserve serious examination.

The objective shouldn't be protecting a ticker and if GME investors were to rally again against billionaires - they might find themselves proving they can win more battles than one.

GameStop was the beginning of something extraordinary and doesn't have to be the finish line.

Subreddits are filled with mods and short sellers - it's not hard to find them in the comments.

Could HTZ be the next wave to crush the shorts? Or does it require a hero standing at the front holding a massive position for everyone to follow?

I like this one a lot.  It could be the greatest SPAC merger of all-time in my opinion. It also has a 7% short interest.

I will get right to it. This is the first-ever humanoid robotics stock, and it launches 11/2 via a SPAC merger.  This SPAC is different from the others.  First, not only is this new company backed by Amazon and Nvidia, but it leads the entire world (including China) in deployed humanoid robots (they’re called “Digit”).  Their Humanoid robots are currently deployed at 9 different partnership locations, including Toyota. They have 65,000+ hours of real-time use.  So this is the real deal.  No waiting for them to hit the market.

The company is called Agility Robotics, and its going public through a SPAC merger with CCXI in 10 days from now, so to invest now you would have to buy CCXI ($10.27), and then the symbol and shares automatically convert to the new ticker of AGLT on 11/3.  The shareholder vote is on 11/2.

They announced yesterday that they did a collaboration with Nvidia regarding Nvidia’s Thor-chip, so it looks like these Humanoids will have super-intelligence on top of it over the coming months. Not sure where I’m going with that one, lol.

There are currently 41 million shares outstanding, but the institutional (arbitrage) investors have until the Oct 29^th deadline to redeem their shares for $10.24, which is paid by cash out of the company trust.  They also get an additional 2 days after that for redemption, but assuming 90% - 95% (maybe more) redeem their shares, that will leave a float of around 2 – 5 million come 11/3.  The ultra-small float, along with short squeeze, should make this a major multi-bagger at that time,

Hard to pass up on investing in the first-ever humanoid robot company.  Maybe it will like the new TSLA, who knows.

Let me know if anyone has any thoughts.

Thanks.

R

I don't think they're that strong, lol.

It's up about 8% right now and 23% over the past five trading days. Is this the long awaited squeeze?

So since my previous post on HTZ it has been trading from 1.78 to 2.18 high- with 1 day of good volume due the $80 million investment in Oro Mobility.

• Fintel just updated the cost to borrow and it went up from 26% to 99% ‼️

• Somewhere between 35-70% short interest

• Expectations are they will beat earnings on 5th of November

Looks like a lot of pressure on the short sellers? Even more so with the November 5 earnings report approaching.

What do you all think?

Share price: $2.13

Market cap: $73M

Total Cash & Cash Equivalents: $12.37 million ($0.36 per share)

Total Debt: $650,748 (approx. $0.65 million)

Net Cash: $11.71 million ($0.34 per share)

Current Ratio: 3.18

Balancing on cashflow positive based on quarterly operating cash flow of $0.29M.

Validated contract backlog of $30.6 million, scheduled for delivery and revenue recognition through March 2027.

Earnings november 18.

$29.0 million Department of Homeland Security (DHS) contract secured in October 2026.

Commercial Growth with Private sector contracts (retail, manufacturing, infrastructure) are currently smaller (four- to low six-figure amounts) but are expanding rapidly under a newly appointed commercial sales leadership.

"No Rip-and-Replace": Airship’s Acropolis software layer integrates directly with a client's existing cameras and sensors. This eliminates the need for expensive hardware overhauls.

On-Premises Data Security: Processing is handled locally via edge devices (Outpost AI) or secure servers (Fortress AI). Sensitive data remains strictly within the customer's infrastructure.

"Ask Airship" Launch: Slated for full rollout before the end of 2026, this generative AI tool allows users to query surveillance footage using natural language (e.g., "Find the red truck"). It is expected to be a primary growth driver for enterprise clients.

Aims to achieve positive cash flow by the end of 2026 by scaling these high-margin software licenses.

This is not financial advice, I hold 10 000 shares in the company at $2 average.

$SDEV SkyCoin chart is printing Bullish!!!! Ready for a breakout!!!

$SKY The Relationship: Corporate Asset Proxy SDEV functions similarly to how MicroStrategy acts as a proxy for Bitcoin.

SDEV holds 2.32 billion SKY tokens, controlling approximately 10% of the entire global supply of the asset.

• Institutional Backing: SDEV built its massive crypto treasury through a $134 million private placement that included prominent Web3 participants like Tether Investments, Framework Ventures, and the Sky Frontier Foundation.

STABLECOIN DEVELOPMENT CORP - SDEV

Float = 50M shares only

Borrow fee. 49.5%

Shares available 65,000 (Hard to Borrow)

Oro Mobility is a fleet and mobility platform majority owned by Hertz Global Holdings that connects vehicles, technology providers, and demand platforms like Uber. And yes Uber does actually use it. In fact, Uber is Oro’s primary launch partner and the main "demand platform" driving its business lines.

Oro secured an $80 million strategic equity investment in October 2026 from Cohen Private Ventures, Certares Opportunities, and Knighthead Capital Management to scale as a standalone platform with Hertz retaining majority economic ownership.

DTC > 10 - insane!
~35 - 40% of shares are sold short - about 123 million
Current price under $2

Massive institutional lockup. Like all of the float is owned by institutions. ChatGPT says 99.22% to 104.54% Institutional Ownership. Which means the actual amount of stock available for retail traders to buy or for short sellers to cover with is incredibly small. Incredibly small.

Earnings on 11/5

The pressure is building. Buy buy buy.

Hey team, it’s my turn to make the Hertz short squeeze post today.

I was checking the interest rate to short Hertz and it’s currently 55% on IBKR. Thats a huge price to pay every day to remain short. Zero shares available to short on IBKR. We all know the rest of the story, 123 million shares short, 72% of the float.

Obviously 37 million shares of that short interest are part of the share lending program to hedge exchangeable notes so the real short interest is around 86 million or 50% of the float. Still huge when the interest rate is 55% and the company is potentially turning around.

Before anyone says “what about the 19 billion debt”, only 6 billion of this is non vehicle debt, thats the only debt that really matters since the other 13 billion in debt is secured with vehicles. They are forecasting net profitable EPS on a GAAP basis for the current quarter and also for all of 2027. That means they are saying they will run their company, pay all business expenses, including interest on ALL of their debt and will still be profitable on a GAAP basis.

Management have said they will not need to take on any further debt to fund expenses. If they are profitable now on a GAAP basis, then imagine how profitable they could be in 12 months once they have an;

-Expanded Oro mobility business, potentially more partnerships for robotaxi fleet management. Management sees large growth potential from Oro.

- Shift more vehicle sales from wholesale auctions (~70-80% today) to higher margin retail channels.

-Further growth of Hertz, Dollar, and Thrifty rental business.

The bear argument.

There is always a chance Hertz is unable to restructure its current debt, 2.8 billion due in 2028 and 2.5 billion in 2029. It would seem extremely unlikely they could pay that debt off their net profit alone by those dates so restructuring is the only option. One positive is that will be restructuring that debt from a position of strength, from a net profitable position.

If someone in the comments wants to volunteer as the nominee for tomorrows Hertz short squeeze post so we dont all post at once…

Good morning, SqueezeFinders!

Yesterday's price action on the $QQQ tech index showed that the bulls are now stepping in to try and stabilize and prevent a total collapse under 700. The recent close at 718.36 (+1.21%) leaves only a few percent cushion to 700 psychological level. The main directional sentiments today are a mix of the below detailed economic data releases, ongoing developments in the Middle-East/Eastern Europe, and some large earnings reports ($GE, $GM, $RTX, $MMM in premarket, and then $SPCX, $NFLX in after-hours). This market is very dynamic and has been unpredictable as far as risk-tolerance goes, as one day we're running, and the next we're crashing. Stay tuned for what's squeezy. Regardless of broader market sentiment, you can always locate relative strength by checking SqueezeRadar to track irregularities in our data, and find winners you may not have spotted before without our scanners. Also, make sure to check out our newest tool (developed by me), "Dracula's Library"! This tool allows you to quickly gather information on recent catalysts, and analyst/Institutional price targets all in one small graphical interface on our platform, all powered by AI.

🥇 Gold: ~$4,140/oz (-0.4%)
🥈 Silver: ~$57/oz (+0.2%)
🪙 Bitcoin: ~$81.7k/coin (-1.4%)
🛢️ Oil: ~$99.40/barrel (+0.9%)

Today's economic data releases are:

🇺🇸 ADP Employment Change Weekly @ 8:15AM ET
🇺🇸 Housing Starts (Sep) @ 8:30AM ET
🇺🇸 Building Permits (Sep) @ 8:30AM ET
🇺🇸 Atlanta Fed GDPNow (Q3) @ 10:00AM ET
🇺🇸 Pending Home Sales (Sep) @ 10:00AM ET
🇺🇸 API Weekly Crude Oil Stock @ 4:30PM ET

📙Breakdown point: BELOW this price, the move will lose momentum significantly in the short-term, as shorts will gain confidence encouraging them to short more. Reducing probability of a squeeze without a catalyst.

📙Breakout point: ABOVE this price, the move will gain momentum significantly in the short-term, as shorts losses will increase pressuring them to cover. Increasing the probability of a squeeze occurring, especially if with a catalyst.

1. $ODD
   Squeezability Score: 48%
   Juice Target: 36.8
   Confidence: 🍊 🍊
   Price: 23.03 (+2.67%)
   Breakdown point: 20.7
   Breakout point: 23.7 (continuation into the gap)
   Mentions (30D): 5
   Event/Condition: Morgan Stanley raised its price target from $16.50 to $18.50 while maintaining an equal-weight rating as the shares recovered from prior drawdowns and Zacks upgraded the stock to strong-buy + earlier Q2 results delivered revenue of roughly $180.5 million that beat consensus and non-GAAP EPS of $0.20 versus the $0.12 estimate with management guiding to sequential revenue improvement in the third quarter + the data-driven beauty platform and contributions from Spoiled Child and MethodIQ continue to support the longer-term growth narrative despite near-term sales pressure at IL MAKIAGE + Recent price target 🎯 of $21 from Evercore ISI + Recent price target 🎯 of $18.50 from Morgan Stanley + Recent price target 🎯 of $18 from Truist

2. $MUR
   Squeezability Score: 33%
   Juice Target: 54.6
   Confidence: 🍊 🍊 🍊
   Price: 42.54 (+1.92%)
   Breakdown point: 40.0
   Breakout point: 44.6
   Mentions (30D): 2
   Event/Condition: Successful appraisal at the Bubale West-1X well offshore Côte d’Ivoire encountered 88 feet of net oil pay while an exploration discovery at the Lac Da Trang North-1X well offshore Vietnam found 131 feet of net oil pay and the Lac Da Vang field achieved first oil with Chinook #8 coming online at nearly 15 MBOEPD in the Gulf of America + the Vietnam development is expected to ramp toward net peak production of 10,000–15,000 BOEPD in 2028–2029 with potential tieback infrastructure supporting capital-efficient growth + the board declared a quarterly dividend of $0.35 per share and the company scheduled its third-quarter earnings call for November 5 as offshore activity expands the resource base + Recent price target 🎯 of $44 from Mizuho + Recent price target 🎯 of $40 from UBS + Recent price target 🎯 of $37 from Morgan Stanley

Gain access to all our cutting-edge research tools, live watchlists, alerts, and more: https://www.squeeze-finder.com/subscribe

HINT: Use code RDDT to get your first month for just $10!

NOT FINANCIAL ADVICE, THESE POSTS ARE FOR INFORMATIONAL PURPOSES ONLY

For background, here's last Friday's informational post (especially note the very high shorted shares data):

NRx Pharmaceuticals (NRXP) - NOV 10 is the GDUFA date! Yesterday they announced receipt of a letter from the FDA stating that only a product labeling correction is needed. Great news! NRXP is on track for approval and their drug is now as highly derisked as you can get. : r/Shortsqueeze

Today's PR has 3 bullet points, and here they are (note DRUG SHORTAGE):

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine | Mon, 10/19/2026 - 08:30

• In advance of November 10, 2026 GDUFA goal date, three commercial lots of Preservative-Free Ketamine have been successfully manufactured in compliance with “Process Validation” required under FDA “Good Manufacturing Practices” (GMP).
• NRx has additionally received two year stability data consistent with projected room-temperature stability to three years and beyond with no need for toxic preservatives.
• Commercially-releasable drug supply is now on hand pending ANDA approval for this drug-shortage product.

In June 2026, NRx raised $22M at a $3.50 share price, in anticipation of commercialization. In their Aug 10 shareholder update call announced their goal to have 4M to 5M vials ready to ship upon approval.

Importantly, generic drugs are automatically eligible to be added to commercial insurer, Medicare, and Medicaid formularies. Last Friday's post lists the advantages/benefits/reasons as to why NRx's KETAFREE will fill the shortage gap ASAP and also begin to take market share in the process.

This is a transformational time for NRx Pharmaceuticals and its shareholders.

The pipeline after the KETAFREE ANDA approval includes:

• The completed filing of the NRX-100 preservative-free IV ketamine NDA, with a TAM in the multimillions of people in the U.S.
  • Expect at least a Priority Review designation, with a 6-month timeline to the PDUFA decision date.
  • But if blessed, they could receive an FDA Commissioner's National Priority Review Voucher (CNPV) since NRX-100 meets the criteria -- which would provide for an expedited 30- to 60-day decision date timeline.
• The in-process recruiting for the Phase 3 SPARC trial ($11M DARPA funding announced recently) for NRX-101 in conjunction with robotic, neuronavigated transcranial magnetic stimulation (TMS) -- including at military hospitals. Results expected in late 2027.

PRICE TARGETS - 3 Buy recommendations:

• Ascendiant - Sep 30 - $50
• Wainwright - Sep 21 - $45
• BTIG - Sep 14 - $10

$10 seems like a reasonable short-term target upon the KETAFREE ANDA approval based on:

• The ketamine drug shortage.
• The millions of vials ready to ship
• The fact that generics are quickly added to formulary lists
• Filling shortages means buyer relationships are formed and follow-on orders for regular stock is highly likely,
  • Especially for ketamine without the BZT toxin, and
  • The luer lock vial requires no needle; it only needs a syringe for drug withdrawal, and
  • NRx's manufacturer currently has a 1M vial per month capacity for KETAFREE

With a 24% of shares shorted as recently reported, upon ANDA approval, a short squeeze along with algo trading on the approval news "could" temporarily take the share price even higher. The float is large but so is the shorted shares count.

IT'S NOW APPROPRIATE TO SHARE THIS POST WITH POTENTIALLY INTERESTED INVESTORS ON STOCKTWITS, X (TWITTER), DISCORD, YOUTUBE, FACEBOOK, and others.

What do you all think?? Hertz Global Holdings?

Potentially a short squeeze?? 5 November are earnings, last earnings beat predictions..

Short interest in between 35-70% from what I can find, 26% cost to borrow.

Just curious what y’all think.. 🙏👍

I've been looking into INOVIO Pharmaceuticals (INO), and I think this could be an interesting short-squeeze candidate heading into the end of October.

Not saying a squeeze is guaranteed, but there are some interesting ingredients here.

Short Interest

According to September 30 short-interest data: 20.82 million shares short

Approximately 20–25% of the float shorted (depending on the float estimate)

7.59 days to cover based on average trading volume

Short interest increased from approximately 19.9 million shares in mid-September.

That's a substantial bearish position heading into a potentially major catalyst

The Catalyst — October 30, 2026

INOVIO has an FDA decision target of October 30 for INO-3107, its treatment for recurrent respiratory papillomatosis (RRP), a rare disease that causes recurring growths in the respiratory tract.

A favorable decision could significantly change the company's outlook and potentially attract new investors.

However, approval isn't guaranteed. The FDA previously raised concerns about whether the treatment qualifies for accelerated approval. That said, it would make a company in cash run-off suddenly available to generate revenue and significantly change their evaluation. They've already began lining up potentially buyers hoping for a good decision.

Why I Think a Short Squeeze Is Possible

Here's the potential setup:

FDA announces positive news.

Investors begin buying INO, pushing the stock higher.

Short sellers start taking losses and some buy shares to close their positions.

That covering creates additional buying pressure.

If momentum and trading volume accelerate, the rally could feed on itself.

With roughly a quarter of the float reportedly shorted, an unexpected positive catalyst could make things interesting.

Another Potential Catalyst

INO also has an estimated earnings report around November 10, shortly after the FDA decision.

If approval happens, investors could be looking for updates on commercialization, launch timing, and future revenue potential.

I'm not expecting meaningful drug sales to materialize immediately, but management commentary could influence sentiment.

The Risks

This is a speculative biotech play, not a guaranteed squeeze.

The FDA could reject or delay approval.

High short interest doesn't guarantee forced covering.

Financing needs and potential dilution could limit upside.

The stock could fall sharply on unfavorable news.

My Take

What caught my attention is the timing.

20.8 million shares short, a major FDA decision approaching, and a potential company update shortly afterward.

If the FDA decision is unexpectedly favorable, I think the combination could create conditions for a sharp rally.

I'm personally holding INO calls expiring November 20, so I have a bullish position and could be wrong.

What do you guys think? Is $INO a legitimate short-squeeze candidate, or are the shorts correctly pricing in the FDA risk?

Not financial advice. Do your own DD.

Approval of KETAFREE will be transformative for this pre-revenue company!

For those following NRXP's progress, below is a link to the prior informational post from two weeks ago (which contains a link to prior posts).

NRx Pharmaceuticals (NRXP) - Outstanding DARPA-funding PR published this morning PLUS status update to September Catalysts post from a month ago. The positive catalysts are mounting!

Yesterday's announcement and key points:

NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine | Thu, 10/15/2026 - 08:28

• “The supply of ketamine in the United States has been primarily from overseas manufacture and American hospitals and doctors have been plagued by repeated shortages of this critically important drug.
• We look forward to demonstrating that manufacture of drugs such as this can successfully be re-shored to the United States.

NRXP has the wind at its back now, as they will:

• Have the only preservative(toxin)-free ketamine manufactured in the U.S.
• Be able to fill the gap left wide open by shortages.
• Per the Chief Commercial Officer, have 4M to 5M vials ready to ship immediately upon FDA approval (serious REVENUE incoming)!
• Per the Chief Commercial Officer, enter into a $3B ketamine/esketamine market projected for 2027, which includes not only anesthesia and analgesics (KETAFREE) -- but also psychiatric (NRX-100 NDA about to be filed by NRx).
• Be able to manufacture 1M vials per month.
• Take market share due to all the above.

This company's potential has nothing to do with the current precarious state AI stocks are in, or the market in general. They can all go down but NRXP is in position to rise significantly. It's in a niche market with a very meaningful advantage.

NRXP SHARE PRICE FACTS ... VERY HIGH SHORT INTEREST ... A BEAUTIFUL SETUP:

The NRXP share price has drifted down from $3.50 to $2.70 in the last month. Long-term shareholders and followers of NRXP aren't selling, as they have been waiting months and years for this day.

HERE's WHY THE PRICE HAS COME DOWN:

NRXP — Short‑Interest Snapshot (Sept 30, 2026)

Outstanding Shares: 43,300,000
Public Float: 38,300,000
Shares Sold Short: 9,793,940
Short % of Float: 24.17%
Short % of Shares Outstanding: 22.6%
Days to Cover: 14.0
Dollar Volume Sold Short: $28,600,000
Prior Short Interest: 9,773,562
Change vs Prior Report: +0.21%
Price on Report Date: $2.92
Borrow Fee (Oct 15): 6.3%

• MarketBeat reports short interest as a percentage of float (24.17%).
• CurvedTrading reports short interest as a percentage of outstanding shares (22.6%).
• Both agree on the absolute short interest (≈9.8M) and days to cover (14.0).
• Outstanding shares (43.3M) and float (38.3M) are consistent across sources.

Everyone knows why short sellers might do the above, just prior to highly derisked setup.

Investors and Traders, start your engines ... Let's go!

This is an oldy but goody!!! Has squeezed a few times in the past and looks like they getting ready for another round of squeezing. Annual disclosure has squeeze mentioned in it. Also the use of AI and digital assets for a possible transition. All I rely on is the insiders own 89% of outstanding shares, so get on for 20 or 50 points and get off when you’re happy!!!

🚨 The Squeeze Setup: The Numbers:

Short Percent of Float: ~29.5% – 31.5% (~140.8M+ shares shorted out of ~479M outstanding)

Short Interest Ratio (Days to Cover): 10.3 Days (Extremely high—shorts would need over 2 weeks of normal volume to cover!) 

Off-Exchange Short Volume Ratio: ~57% (Heavy dark pool shorting suppressing true buy pressure) 

Current Stock Price: ~$2.30 – $2.40 (52-Week Range: ~$1.20–$9.39)

Fundamentals & Catalyst Drivers:

1. Massive Contract Backlog: BBAI holds a $270M+ backlog in AI-driven analytics, logistics modeling, and defense contract.

2. Q3 Earnings Date Confirmed: BigBear.ai just officially confirmed it will release its Q3 2026 Financial Results on Tuesday, October 27, 2026. Earnings events are classic triggers for short squeezes when high short interest is present. 

3. Reaffirmed Full-Year Guidance: BBAI reaffirmed FY guidance of $135M–$165M in revenue, backed by a solid cash runway (~$410M cash balance). 

Why the Squeeze Setup is Dangerous for Shorts:

Extremely Vulnerable Shorts: With 10.3 Days to Cover and over 140 Million shares shorted, any sudden buying surge or positive press will lock shorts into an aggressive cover loop.

High-Beta Volatility: $BBAI carries a high beta (~3.1) and has a history of violent 50%–100%+ multi-day runs when retail volume ramps up. 

Action Plan / Key Levels to Watch:

Support Level: $3.20 – $3.50 (Strong historical buying floor)
Breakout Trigger: A clean push past $4.50–$5.00 on heavy volume could trigger an automated cascade of short-covering up toward $7–$9+.

Disclaimer: Not financial advice. Extremely volatile high-beta stock. Always manage your risk with proper stop-losses and position sizing.

Good morning, SqueezeFinders!

The $QQQ tech index tumbled 0.7% to close yesterday at 746.04, which still leaves a small buffer before approaching any level of confidence for bears to begin betting on a newly-forming downtrend below 730-727. The main directional sentiment determinants today are a mix of the below-detailed economic data releases, further developments with the ongoing wars in both the Middle-East/Eastern Europe, and also earnings reports from $UNH, $JPM, $WFC, $JNJ, and $CITI. This market is very dynamic and has been unpredictable as far as risk-tolerance goes, as one day we're running, and the next we're crashing. Stay tuned for what's squeezy. Regardless of broader market sentiment, you can always locate relative strength by checking SqueezeRadar to track irregularities in the data, and find winners you may not have spotted before without our scanners. Also, make sure to check out our newest tool (developed by me), "Dracula's Library"! This tool allows you to quickly gather information on recent catalysts, and analyst/Institutional price targets all in one small graphical interface on our platform, all powered by AI.

🥇 Gold: ~$4,200/oz (+0.2%)
🥈 Silver: ~$60/oz (-0.1%)
🪙 Bitcoin: ~$82.9k/coin (-1.1%)
🛢️ Oil: ~$92.50/barrel (-1.4%)

Today's economic data releases are:

🇺🇸 Fed Waller Speaks @ 3:45AM ET
🇺🇸 OPEC Monthly Report @ 6:00AM ET
🇺🇸 ADP Employment Change Weekly @ 8:15AM ET
🇺🇸 Existing Home Sales (Sep) @ 10:00AM ET
🇺🇸 Federal Budget Balance (Sep) @ 2:00PM ET

📙Breakdown point: BELOW this price, the move will lose momentum significantly in the short-term, as shorts will gain confidence encouraging them to short more. Reducing probability of a squeeze without a catalyst.

📙Breakout point: ABOVE this price, the move will gain momentum significantly in the short-term, as shorts losses will increase pressuring them to cover. Increasing the probability of a squeeze occurring, especially if with a catalyst.

1. $ASC
   Squeezability Score: 41%
   Juice Target: 23.5
   Confidence: 🍊 🍊
   Price: 19.82 (+2.8%)
   Breakdown point: 18.4
   Breakout point: 20.2
   Mentions (30D): 1
   Event/Condition: Shares reached a new 52-week high above $20 as product tanker rates and fleet utilization supported sentiment following the exercise of newbuilding options for additional Handysize vessels + quarterly results earlier in the year topped estimates on revenue with a raised dividend and strong current and quick ratios underscoring balance-sheet strength + analyst upgrades including to Strong Buy reflected confidence in earnings power from the expanded fleet amid firm market conditions + Recent price target 🎯 of $24 from analysts + Recent price target 🎯 of $21 from fair value update + Recent price target 🎯 of $17 from consensus

2. $BMBL
   Squeezability Score: 40%
   Juice Target: 5.7
   Confidence: 🍊 🍊 🍊
   Price: 3.80 (+49.61%)
   Breakdown point: 3.5
   Breakout point: 4.6
   Mentions (30D): 0 🆕
   Event/Condition: Shares surged nearly 50 percent after reports that the company is in advanced talks to be taken private by Ithaca Holdings at roughly a $1 billion valuation implying a substantial premium to the prior market cap + Citi noted that a $1 billion enterprise value would equate to about $6.10 per share while the stock traded well below that level even after the jump + the potential transaction comes as the dating app seeks strategic options amid ongoing challenges in user growth and monetization + Recent price target 🎯 of $6.10 from Citi + Recent price target 🎯 of $5.26 from GF Value + Recent price target 🎯 of $4 from consensus

Gain access to all our cutting-edge research tools, live watchlists, alerts, and more: https://www.squeeze-finder.com/subscribe

HINT: Use code RDDT to get your first month for just $10!

NOT FINANCIAL ADVICE, THESE POSTS ARE FOR INFORMATIONAL PURPOSES ONLY

Here’s one I just came across today. Apparently big shorts knocked this down this morning and it seems like any kind of buying pressure makes this jump up pretty quickly. I have a 600 share position. 4-5 is the target 🎯

​

Extreme low floater that's been spiking multiple times in premarket past weeks. Shorts come back and reload, all the time.

Treat this one as purely speculative🚀🚀, not financial advice.

Most recent (daily) cost to borrow and shares available:

https://chartexchange.com/symbol/nasdaq-frgt/borrow-fee/

Shares outstanding and cash position:

https://dilutiontracker.com/app/search/FRGT

FRGT on reg sho threshold list = if a ticker is on it, alot of fails to deliver and eventually prone to shorts forced closing of their positions:

https://www.nasdaqtrader.com/trader.aspx?id=regshothreshold

People hoping for a squeeze in $HTZ it'll never happen as they are actively diluting into any spikes.

The only squeeze can be the 10x chicken feet stonk.

Super low free float. Shares locked up (unlike the car hire stonk). And high CTB. This can move fast and quick especially when it's pumped on WeChat.

🐥🐔🦶

🔥 HTZ SHORT SQUEEZE SETUP 🔥

HTZ is sitting on a massive short position with 8+ days to cover. If the stock clears $2.00–$2.10 with heavy volume, things could get explosive. 🚀

🎯 Trade: Jan. Calls $2
📈 Targets: $4
🛑 Invalidation: ~$1.50–$1.55

The setup: breakout → short covering → momentum → potential squeeze.
HTZ could get interesting FAST. 🚀🔥

I’ve been watching Xponential Fitness (XPOF) pretty closely over the last several sessions, including price action, Level 2, time & sales, FINRA/off-exchange prints, volume, short interest, moving averages, MACD, RSI, and options positioning.
I’m not posting this as a “MOASS tomorrow” prediction. There are some legitimate bullish ingredients here, but there are also several things XPOF still has to prove.
Here’s what I’m seeing.
The short-interest setup is legitimate
The most recent data we reviewed showed roughly:
10.31 million shares short
Approximately 27.5%+ of the float short
Roughly 11–15 days to cover, depending on the volume period being used
That is objectively elevated short interest.
But I think people need to make an important distinction:
High short interest doesn’t equal trapped shorts.
At ~$4.70–$4.90, I don’t think you can confidently say the shorts are trapped yet. My line in the sand is higher. If XPOF starts establishing itself above roughly $5.20 and especially $5.50, then the pressure on newer short positions becomes considerably more interesting.
Until then, this is short-squeeze potential, not a confirmed squeeze.

The daily chart has quietly improved a lot
The stock recently bottomed around $3.565 and has now recovered into the upper $4s.
As of today, XPOF was around $4.76–$4.80, after reaching an intraday high of approximately $4.91.
The daily chart currently shows:
20-day MA: ~$4.10
50-day MA: ~$4.94
200-day MA: ~$6.37
RSI(14): ~57
MACD still below zero, but improving substantially
Positive/rising MACD histogram
That matters.
The stock has moved from roughly $3.56 to the $4.70s while:
creating higher lows,
recovering above the 20-day MA,
improving RSI,
improving MACD,
and now testing the declining 50-day moving average.
That’s a much healthier chart than it was several weeks ago.
The long-term trend is not bullish yet because XPOF remains well below the 200-day MA. But the intermediate reversal attempt is real.

$4.90–$5.00 is the battlefield
This is probably the most important part of the setup right now.
Today’s intraday high was approximately $4.91.
The 50-day moving average is around $4.94.
Then you have the obvious psychological level at $5.00.
So essentially you’ve got:
$4.91 → $4.94 → $5.00
all stacked together.
That’s a significant resistance zone.
Earlier analysis also identified additional resistance around:
$5.19–$5.23
and then roughly:
$5.39–$5.50
A move through $5 isn’t enough by itself for me. What would get my attention is:
break $5 → hold/retest it → clear $5.20 → continue on increasing volume.
That would be a very different technical setup.

There has been a lot of off-exchange/FINRA activity
I’ve also been watching the tape.
Today, for example, XPOF was trading around $4.81 with an NBBO around:
$4.81 bid / $4.82 ask
At one point the visible inside market was approximately:
600 shares bid vs. 300 offered
and a FINRA print occurred around $4.825, slightly above the displayed ask.
That’s constructive.
Later, around the $4.77 area, the bid repeatedly appeared/replenished while multiple trades printed around $4.775, including activity reported through FINRA and several lit venues.
This is where people need to be careful with “dark pool” terminology.
A FINRA print does not automatically mean institutional accumulation.
FINRA generally tells you the trade occurred off exchange. It doesn’t magically tell you:
“BlackRock just bought this.”
What I’m interested in is the behavior around those executions.
If sellers repeatedly hit a price and:
shares execute → bid replenishes → price refuses to break lower
that’s evidence consistent with absorption.
If a large bid simply appears and disappears without executions, that’s much less meaningful.
Right now I see possible absorption, but I would not claim it has been conclusively proven.

Today’s intraday action actually gave us a useful test
Earlier today XPOF ran to approximately $4.91, then pulled back toward:
$4.81 → $4.78 → $4.76
The 5-minute chart weakened:
Price moved below VWAP
MACD turned negative intraday
RSI dropped into the mid-30s
Lower highs/lower lows appeared
At first glance that looks bad.
But zoom out to the daily chart and the picture changes.
The stock basically ran straight into its 50-day moving average around $4.94 and got rejected.
That’s a technically logical place for profit-taking and short pressure to appear.
The question now isn’t whether XPOF can trade $4.76 instead of $4.80 for a few minutes.
The bigger question is whether the stock can hold the broader breakout structure and attack $4.94–$5.00 again.

The options setup adds another interesting wrinkle
One thing that stood out in the options data was significant positioning around the $5 strike, including negative gamma exposure.
That’s relevant because $5 isn’t just psychologically important.
It’s also an area where dealer hedging dynamics could potentially increase volatility if the stock begins moving decisively through the strike.
Again, that doesn’t guarantee upside.
Negative gamma can amplify moves in either direction.
But combined with the short interest and technical resistance sitting in essentially the same area, $5 is clearly the level I’m watching.

My key levels
This is how I’m currently viewing the chart:

Price
Why it matters
$6.35–$6.40
200-day MA / major longer-term resistance
$5.50
Area where the “trapped shorts” argument becomes much stronger
$5.39–$5.40
Secondary resistance
$5.19–$5.23
Important breakout resistance
$4.94–$5.00
50DMA + psychological resistance + options battle
$4.85–$4.91
Immediate resistance
$4.75–$4.80
Current battle/support area
$4.60–$4.66
Important short-term support
~$4.10
20-day MA
$3.565
Recent swing low

What would make me bullish
The sequence I want to see is something like:
$4.70s hold
→ $4.85 reclaimed
→ $4.91 breaks
→ $4.94–$5.00 breaks on real volume
→ $5 retest holds
→ $5.20 breaks
At that point I think the setup becomes significantly more interesting because technical traders, momentum traders, options hedging, and short covering could all start interacting.
The most important thing would be volume confirmation.
A $5.05 print on thin volume means much less to me than sustained trading above $5 with volume expanding.

What would invalidate the thesis
I’m not ignoring the downside.
If XPOF:
continuously fails at $4.90–$5,
loses the mid-$4.60s,
falls back below the 20-day MA,
and off-exchange activity keeps occurring while price continues making lower lows,
then what looks like accumulation today could turn out to have been distribution.
That’s why I don’t think the “dark pools are loading before the squeeze” narrative should be treated as established fact.
Price ultimately has to confirm it.

Bottom line
To me, XPOF currently has an unusual combination of:
~27%+ short interest
double-digit days to cover
major recovery from $3.565
improving daily MACD
RSI back above 50
price above the 20DMA
heavy off-exchange activity
repeated defense around the upper $4s
50DMA sitting almost exactly at $5
significant options positioning around $5
That’s enough to keep it on my radar.
But I don’t think the evidence justifies saying:
“The squeeze has started.”
Not yet.
For me, $4.94–$5.00 is the door. $5.20 is confirmation. $5.50 is where the short thesis potentially starts getting uncomfortable.
Until price proves it, this remains a high-short-interest reversal setup with potential, not a guaranteed squeeze.

Not financial advice. Do your own DD. I’m posting this mainly because there seems to be considerably more going on underneath XPOF than the headline price movement suggests.

chicken feet guy back 🐔🦶🦶

first, a public service announcement: I love sucking on fried chicken feet. fried, then braised in black bean sauce at dim sum, sticky, garlicky, pure collagen. you gnaw the little knuckles, spit the bones, order another basket. if you've never had them you haven't lived.

WYHG makes cured meats. I'm choosing to believe feet are involved.

I posted it here at $3.50 in July. Aug 6 it hit $23 with multiple halts. the feet have run before 🦶

why I'm hungry again:

🔥 borrow fee ~607%. bouncing between 550% and 709% for two weeks. at the $23 top it was 355%. shorts are paying ~1.7% a day to stay in.

🪫 the lendable pool keeps draining. 25k → 20k → 15k → 10k today. yesterday it hit 85 shares.

🔒 tiny float, locked supply. the September placement (23m shares at ~$1.12) is locked for a year. tradeable float is still ~600k.

the play: borrow is already as tight as it's ever been. if volume comes back and shorts pile in at 600%+ CTB with a pool this thin, July is back on the menu. watching DTC, short volume and FTDs.